# US 2024/0189394 A1 · Methods of using and compositions containing dulaglutide

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189394 A1
- Document ID: US20240189394A1
- Status: Published application
- Kind: A1
- Application number: 18/149,982
- Filed: 2023-01-04
- Published: 2024-06-13
- Earliest claimed: 2017-11-21
- Assignees: Eli Lilly and Company
- Applicants: Eli Lilly and Company
- Inventors: David Andrew Cox; Zvonko Milicevic; Lai San Tham; Andrew Gordon Werner; David Bradley Woodward
- Web page: https://patentgrep.com/patent/US20240189394A1

## CPC

- A61K 38/26: Glucagons
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to methods of using new doses of dulaglutide and compositions containing such higher doses of dulaglutide

## Claims

### Claim at position 1

-35. (canceled)

### Claim 36

A method of improving glycemic control in a subject in need thereof with type 2 diabetes comprising administering dulaglutide to the subject, wherein the administering comprises
a) a starting dose of 0.75 mg of dulaglutide administered once weekly:
b) increasing the dose to 1.5 mg of dulaglutide administered once weekly for at least 4 weeks: and
c) further increasing the once weekly administered dulaglutide dose to a dose of 3.0 mg.

### Claim 37 (depends on 36)

The method of claim 36, further comprising administering the 3.0 mg dulaglutide dose once weekly for a time sufficient to provide additional body weight reduction compared to body weight reduction resulting from administering the once weekly 1.5 mg dose of dulaglutide.

### Claim 38 (depends on 36)

The method of claim 36, wherein each dulaglutide dose is provided as a 0.5 mL aqueous solution containing 0.75 mg. 1.5 mg, or 3.0 mg of dulaglutide.

### Claim 39

A method of improving glycemic control in a subject in need thereof with type 2 diabetes comprising administering dulaglutide by injection to the subject, wherein the administering comprises
a) a starting dose of 0.75 mg of dulaglutide administered once weekly:
b) increasing the dose to 1.5 mg of dulaglutide administered once weekly for at least 4 weeks: and
c) further increasing the once weekly administered dulaglutide dose by 1.5 mg increments after at least 4 weeks of administering a prior dose, up to a maximum dose of 4.5 mg.

### Claim 40 (depends on 39)

The method of claim 39, further comprising administering the 4.5 mg dulaglutide dose once weekly for a time sufficient to provide additional body weight reduction compared to body weight reduction resulting from administering the once weekly 1.5 mg dose of dulaglutide.

### Claim 41 (depends on 39)

The method of claim 39, wherein each dulaglutide dose is provided as a 0.5 mL aqueous solution containing 0.75 mg, 1.5 mg, 3.0 mg, or 4.5 mg of dulaglutide.

### Claim 42 (depends on 41)

The method of claim 41, wherein each dulaglutide dose is provided in an autoinjector.

### Claim 43 (depends on 39)

The method of claim 39, wherein the subject is being administered metformin.

### Claim 44

A method of improving glycemic control in a subject in need thereof with type 2 diabetes comprising administering to the subject a 3.0 mg dose of dulaglutide once weekly by injection.

### Claim 45 (depends on 44)

The method of claim 44, wherein the 3.0 mg dose of dulaglutide is provided in an autoinjector comprising a 0.5 ml aqueous solution containing 3.0 mg of dulaglutide.

### Claim 46 (depends on 44)

The method of claim 44, wherein the subject is being administered metformin.

### Claim 47 (depends on 44)

The method of claim 44, wherein, prior to administering the 3.0 mg dose of dulaglutide once weekly, the subject is administered by injection an initial dose of 0.75 mg of dulaglutide once weekly followed by a dose of 1.5 mg dulaglutide once weekly for at least 4 weeks.

### Claim 48

A method of improving glycemic control in a subject in need thereof with type 2 diabetes comprising administering to the subject a 4.5 mg dose of dulaglutide once weekly by injection.

### Claim 49 (depends on 48)

The method of claim 48, wherein the 4.5 mg dose of dulaglutide is provided in an autoinjector comprising a 0.5 ml aqueous solution containing 4.5 mg of dulaglutide.

### Claim 50 (depends on 48)

The method of claim 48, wherein the subject is being administered metformin.

### Claim 51 (depends on 48)

The method of claim 48, wherein, prior to administering the 4.5 mg dose of dulaglutide once weekly, the subject is administered by injection an initial dose of 0.75 mg of dulaglutide once weekly followed by a dose of 1.5 mg dulaglutide once weekly for at least 4 weeks, followed by a dose of 3.0 mg dulaglutide once weekly for at least 4 weeks.
